

In: Ivert LU, Johansson EK, Dal H, Lindelöf B, Wahlgren CF, Bradley M. Association Between Atopic Dermatitis and Cardiovascular Disease: A Nationwide Register-based Case-control Study from Sweden. *Acta Derm Venereol* 2019; 99: 865–870 a sentence in the Result is incorrect. The changes are given in bold in the following sentence:

In total, 107,657 patients with AD were identified. After applying the exclusion criteria, 104,823 patients with AD and 1,022,435 matching controls remained, as shown in the flow chart (Fig. 1).

Corrected: In total, 107,657 patients with AD were identified. After applying the exclusion criteria, **104,832 patients** with AD and 1,022,435 matching controls remained, as shown in the flow chart (Fig. 1).

Also, Fig. 1 (highlighted) and Table II have been somewhat modified (highlighted):




Table II. Risk of coronary artery disease and stroke in patients with atopic dermatitis (AD) compared with individuals without AD

	Cases n = 104,832 n (%)	All (crude) ^a OR (95% CI)	All (fully adjusted) ^b OR (95% CI)	Men (crude) ^a OR (95% CI)	Men (fully adjusted) ^b OR (95% CI)	Women (crude) ^a OR (95% CI)	Women (fully adjusted) ^b OR (95% CI)
<i>Angina pectoris</i>							
AD total	2,719 (2.59)	1.18 (1.13–1.23)	1.13 (1.08–1.19)	1.15 (1.08–1.22)	1.10 (1.03–1.18)	1.21 (1.14–1.28)	1.16 (1.09–1.24)
Non-severe AD	2,194 (2.09)	1.16 (1.10–1.21)	1.13 (1.08–1.19)	1.15 (1.07–1.23)	1.12 (1.04–1.20)	1.17 (1.09–1.25)	1.15 (1.08–1.24)
Severe AD	525 (0.50)	1.27 (1.15–1.40)	1.11 (1.00–1.24)	1.16 (1.00–1.34)	1.04 (0.89–1.21)	1.38 (1.20–1.57)	1.19 (1.04–1.37)
Systemic treatment ^c total	205 (0.20)	1.37 (1.17–1.61)	1.02 (0.87–1.21)	1.26 (1.00–1.58)	0.99 (0.78–1.26)	1.50 (1.20–1.87)	1.08 (0.85–1.35)
<i>Myocardial infarction (MI)</i>							
AD total	12,281 (11.71)	1.10 (1.04–1.15)	1.07 (1.02–1.12)	1.15 (1.07–1.22)	1.12 (1.05–1.20)	1.03 (0.96–1.11)	1.01 (0.94–1.08)
Non-severe AD	10,584 (10.09)	1.08 (1.03–1.14)	1.07 (1.02–1.13)	1.16 (1.08–1.24)	1.15 (1.07–1.23)	0.99 (0.92–1.08)	0.98 (0.91–1.07)
Severe AD	1,697 (1.62)	1.14 (1.03–1.27)	1.03 (0.92–1.15)	1.09 (0.94–1.26)	1.01 (0.87–1.18)	1.20 (1.03–1.40)	1.06 (0.91–1.24)
Systemic treatment ^c total	167 (0.16)	1.26 (1.06–1.50)	0.99 (0.82–1.18)	1.17 (0.93–1.48)	0.98 (0.76–1.25)	1.38 (1.07–1.78)	1.03 (0.79–1.34)
<i>Stroke</i>							
AD total	6,829 (6.51)	1.07 (1.02–1.13)	1.04 (0.99–1.09)	1.13 (1.05–1.22)	1.09 (1.01–1.17)	1.03 (0.96–1.10)	1.00 (0.93–1.07)
Non-severe AD	5,859 (5.59)	1.02 (0.97–1.08)	1.00 (0.94–1.06)	1.09 (1.01–1.19)	1.06 (0.98–1.16)	0.96 (0.89–1.04)	0.95 (0.88–1.02)
Severe AD	970 (0.93)	1.32 (1.19–1.47)	1.19 (1.07–1.33)	1.32 (1.11–1.56)	1.20 (1.01–1.43)	1.33 (1.15–1.53)	1.19 (1.03–1.37)
Systemic treatment ^c total	158 (0.15)	1.47 (1.23–1.75)	1.18 (0.98–1.41)	1.32 (0.99–1.75)	1.09 (0.82–1.46)	1.58 (1.26–1.99)	1.23 (0.98–1.56)
<i>Death from MI/Stroke</i>							
AD total	637 (0.6)	1.00 (0.92–1.09)	1.01 (0.93–1.10)	1.04 (0.92–1.17)	1.05 (0.92–1.18)	0.96 (0.85–1.09)	0.98 (0.87–1.10)
Non-severe AD	463 (0.5)	0.97 (0.88–1.07)	0.99 (0.90–1.10)	1.02 (0.89–1.18)	1.04 (0.90–1.20)	0.92 (0.80–1.07)	0.95 (0.82–1.09)
Severe AD	174 (0.8)	1.08 (0.91–1.27)	1.04 (0.88–1.23)	1.08 (0.84–1.38)	1.05 (0.82–1.35)	1.07 (0.86–1.35)	1.03 (0.82–1.30)
Systemic treatment ^c total	33 (0.03)	0.95 (0.66–1.37)	0.84 (0.58–1.21)	0.71 (0.40–1.27)	0.65 (0.37–1.17)	1.21 (0.75–1.94)	1.02 (0.63–1.65)

^aCrude (sex- and age-adjusted). ^bAdjusted for cardiovascular comorbidities (diabetes mellitus, hyperlipidemia, hypertension) and years of education. ^cSubgroup of patients with severe AD receiving systemic treatment (methotrexate, azathioprine, cyclosporine A or mycophenolate mofetil). Significant differences in fully adjusted models in bold. OR: odds ratio; CI: confidence interval.

Corrected

Table II. Risk of coronary artery disease and stroke in patients with atopic dermatitis (AD) compared with individuals without AD

	Cases n = 104,832 n (%)	All (crude) ^a OR (95% CI)	All (fully adjusted) ^b OR (95% CI)	Men (crude) ^a OR (95% CI)	Men (fully adjusted) ^b OR (95% CI)	Women (crude) ^a OR (95% CI)	Women (fully adjusted) ^b OR (95% CI)
<i>Angina pectoris</i>							
AD total	2,719 (2.59)	1.18 (1.13–1.23)	1.13 (1.08–1.19)	1.15 (1.08–1.22)	1.10 (1.03–1.18)	1.21 (1.14–1.28)	1.16 (1.09–1.24)
Non-severe AD	2,194 (2.09)	1.16 (1.10–1.21)	1.13 (1.08–1.19)	1.15 (1.07–1.23)	1.12 (1.04–1.20)	1.17 (1.09–1.25)	1.15 (1.08–1.24)
Severe AD	525 (0.50)	1.27 (1.15–1.40)	1.11 (1.00–1.24)	1.16 (1.00–1.34)	1.04 (0.89–1.21)	1.38 (1.20–1.57)	1.19 (1.04–1.37)
Systemic treatment ^c total	205 (0.20)	1.37 (1.17–1.61)	1.02 (0.87–1.21)	1.26 (1.00–1.58)	0.99 (0.78–1.26)	1.50 (1.20–1.87)	1.08 (0.85–1.35)
<i>Myocardial infarction (MI)</i>							
AD total	2,264 (2.16)	1.10 (1.04–1.15)	1.07 (1.02–1.12)	1.15 (1.07–1.22)	1.12 (1.05–1.20)	1.03 (0.96–1.11)	1.01 (0.94–1.08)
Non-severe AD	1,801 (1.72)	1.08 (1.03–1.14)	1.07 (1.02–1.13)	1.16 (1.08–1.24)	1.15 (1.07–1.23)	0.99 (0.92–1.08)	0.98 (0.91–1.07)
Severe AD	463 (0.44)	1.14 (1.03–1.27)	1.03 (0.92–1.15)	1.09 (0.94–1.26)	1.01 (0.87–1.18)	1.20 (1.03–1.40)	1.06 (0.91–1.24)
Systemic treatment ^c total	167 (0.16)	1.26 (1.06–1.50)	0.99 (0.82–1.18)	1.17 (0.93–1.48)	0.98 (0.76–1.25)	1.38 (1.07–1.78)	1.03 (0.79–1.34)
<i>Stroke</i>							
AD total	1,975 (1.88)	1.07 (1.02–1.13)	1.04 (0.99–1.09)	1.13 (1.05–1.22)	1.09 (1.01–1.17)	1.03 (0.96–1.10)	1.00 (0.93–1.07)
Non-severe AD	1,538 (1.47)	1.02 (0.97–1.08)	1.00 (0.94–1.06)	1.09 (1.01–1.19)	1.06 (0.98–1.16)	0.96 (0.89–1.04)	0.95 (0.88–1.02)
Severe AD	437 (0.42)	1.32 (1.19–1.47)	1.19 (1.07–1.33)	1.32 (1.11–1.56)	1.20 (1.01–1.43)	1.33 (1.15–1.53)	1.19 (1.03–1.37)
Systemic treatment ^c total	158 (0.15)	1.47 (1.23–1.75)	1.18 (0.98–1.41)	1.32 (0.99–1.75)	1.09 (0.82–1.46)	1.58 (1.26–1.99)	1.23 (0.98–1.56)
<i>Death from MI/Stroke</i>							
AD total	637 (0.6)	1.00 (0.92–1.09)	1.01 (0.93–1.10)	1.04 (0.92–1.17)	1.05 (0.92–1.18)	0.96 (0.85–1.09)	0.98 (0.87–1.10)
Non-severe AD	463 (0.44)	0.97 (0.88–1.07)	0.99 (0.90–1.10)	1.02 (0.89–1.18)	1.04 (0.90–1.20)	0.92 (0.80–1.07)	0.95 (0.82–1.09)
Severe AD	174 (0.17)	1.08 (0.91–1.27)	1.04 (0.88–1.23)	1.08 (0.84–1.38)	1.05 (0.82–1.35)	1.07 (0.86–1.35)	1.03 (0.82–1.30)
Systemic treatment ^c total	33 (0.03)	0.95 (0.66–1.37)	0.84 (0.58–1.21)	0.71 (0.40–1.27)	0.65 (0.37–1.17)	1.21 (0.75–1.94)	1.02 (0.63–1.65)

^aCrude (sex- and age-adjusted). ^bAdjusted for cardiovascular comorbidities (diabetes mellitus, hyperlipidemia, hypertension) and years of education. ^cSubgroup of patients with severe AD receiving systemic treatment (methotrexate, azathioprine, cyclosporine A or mycophenolate mofetil). Significant differences in fully adjusted models in bold. OR: odds ratio; CI: confidence interval.